Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:CLA CVE:EMH On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCLAColonnade Acquisition$25.04$12.38$9.54▼$17.73$625.93MN/A1.35 million shs3,800 shsEMHEmerald Health TherapeuticsC$0.26-3.8%C$0.26C$0.15▼C$0.53C$52.28MN/A644,760 shs384,329 shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCLAColonnade Acquisition0.00%0.00%0.00%0.00%0.00%EMHEmerald Health Therapeutics0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCLAColonnade AcquisitionN/AN/AN/AN/AN/AN/AN/AN/AEMHEmerald Health TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCLAColonnade Acquisition 0.00N/AN/AN/AEMHEmerald Health Therapeutics 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCLAColonnade AcquisitionN/AN/AN/AN/AN/AN/AEMHEmerald Health TherapeuticsC$13.02M4.02C$0.33 per share0.78C$0.40 per share0.64Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCLAColonnade AcquisitionN/AN/A0.00∞N/AN/AN/AN/AN/AEMHEmerald Health TherapeuticsN/A-C$0.70N/A∞N/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCLAColonnade AcquisitionN/AN/AN/AN/AN/AEMHEmerald Health TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCLAColonnade AcquisitionN/A14.6514.65EMHEmerald Health Therapeutics35.452.972.61Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCLAColonnade AcquisitionN/AEMHEmerald Health TherapeuticsN/AInsider OwnershipCompanyInsider OwnershipCLAColonnade AcquisitionN/AEMHEmerald Health TherapeuticsN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCLAColonnade AcquisitionN/A25.00 millionN/ANot OptionableEMHEmerald Health Therapeutics161205.03 millionN/ANot OptionableCLA, EMH, ZNWD, and MET1 HeadlinesRecent News About These CompaniesWomen’s Health Therapeutics Market Size to Reach USD 61.6 Billion by 2032, Driven by Rising Awareness & Technological Advancements - SNS InsiderOctober 17, 2024 | finance.yahoo.comEmerald PrincessMay 24, 2024 | travel.usnews.comUniversity Hospitals Elyria Medical CenterSeptember 22, 2023 | health.usnews.comDigital Therapeutics: Next wave in managing chronic medical conditionsSeptember 13, 2023 | health.economictimes.indiatimes.comThe Digital Therapeutics Market Is GangbustersAugust 29, 2023 | mddionline.comMDigital Therapeutics (DTx) For Mental Health Market is Booming and Expected to Grow at a CAGR of 27.42% to 2031 | InsightAce StudyJuly 30, 2023 | finance.yahoo.comEmerald Isle’s Lee Avenue to close again soon as culvert project restartsJuly 15, 2023 | carolinacoastonline.comCEfficient Market Hypothesis (EMH): Definition and CritiqueJuly 12, 2023 | investopedia.comRevolutionizing mental health treatment: Vistagen Therapeutics' nasal spray solutionJune 20, 2023 | finance.yahoo.comMenarini Group Shares New Analysis from EMERALD Clinical Study of ORSERDU® (Elacestrant) in Metastatic Breast Cancer at ASCO 2023May 29, 2023 | thaipr.netTEmerald Care Center TulsaMay 4, 2023 | health.usnews.comEmerald ReegApril 25, 2023 | health.usnews.comEmerald Expositions GAAP EPS of $0.06, revenue of $93.6MMarch 14, 2023 | msn.comTahoe's Emerald Bay freezes over for first time in decades amid atmospheric riverMarch 13, 2023 | sfgate.comVisus Therapeutics to Attend TD Cowen’s 43rd Annual Health Care ConferenceMarch 4, 2023 | venturebeat.comVEmerald community raising money for local dialysis services after political campaigns failFebruary 24, 2023 | abc.net.auANew Digital Therapeutics Company Takes a 'Swing' at FibromyalgiaFebruary 22, 2023 | mddionline.comMEmerald Asset Management PA, LLC 30th Annual Emerald Groundhog Day Investment Forum Opens Amid a Stormy 2023 Investment YearJanuary 14, 2023 | finance.yahoo.comEmerald Health Therapeutics Inc (TBD.BE)January 4, 2023 | finance.yahoo.comEmerald Health Therapeutics Announces Revocation of Management Cease Trade OrderJuly 12, 2022 | finance.yahoo.comTop HeadlinesView All Headlines3 Catalysts Converge on Intel Ahead of a Critical Earnings ReportBy Jeffrey Neal Johnson | July 13, 2025View 3 Catalysts Converge on Intel Ahead of a Critical Earnings ReportAST SpaceMobile: A New Asset Class Held Down by Outdated ModelsBy Jeffrey Neal Johnson | July 23, 2025View AST SpaceMobile: A New Asset Class Held Down by Outdated ModelsGameStop: Clarity Brings Renewed Confusion for Meme StockBy Thomas Hughes | July 22, 2025View GameStop: Clarity Brings Renewed Confusion for Meme StockAlphabet: Technical Momentum Is Starting to TurnBy Ryan Hasson | July 10, 2025View Alphabet: Technical Momentum Is Starting to TurnAnalysts Bet Big on Uber Stock's Expansion in Autonomous DrivingBy Gabriel Osorio-Mazilli | July 14, 2025View Analysts Bet Big on Uber Stock's Expansion in Autonomous DrivingCLA, EMH, ZNWD, and MET1 Company DescriptionsColonnade Acquisition NYSE:CLAColonnade Acquisition Corp. is a blank check company that acquires assets and businesses through a merger, share exchange, share purchase, reorganization, and similar business combination. The company was founded in 2020 and is based in West Palm Beach, FloridaEmerald Health Therapeutics CVE:EMHC$0.26 -0.01 (-3.77%) As of 04/26/2021Emerald Health Therapeutics, Inc., together with its subsidiaries, produces and sells medical cannabis for medical purpose in Canada. The company is also involved in developing natural health products. It offers dried cannabis strains, pre-rolls, and cannabis oil products to its medical patients. The company was formerly known as T-Bird Pharma Inc. and changed its name to Emerald Health Therapeutics, Inc. in June 2015. Emerald Health Therapeutics, Inc. is headquartered in Vancouver, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/28 - 08/01 Alphabet Gains Momentum as Sentiment on Wall Street Improves Amazon's Earnings: What Comes Next and How to Play It Apple Stock: Big Earnings, Small Move—Time to Buy? Tesla Teams With Samsung—Will Other Chipmakers Follow? Will Hims & Hers Fall Along With Novo Nordisk? UPS's 7.5% Dividend: A Blue-Chip Stock on a Once-in-a-Decade Sale AbbVie Stock Eyes Breakout as Pipeline and Profits Grow Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
